Third Wave Acquisition To Drive PE Biosystems Revenue Growth In FY 2000
This article was originally published in The Gray Sheet
Executive Summary
PE Biosystems Group's acquisition of Third Wave Technologies, announced Jan. 24, should help the company reach its top-line growth target in fiscal 2000, the firm maintained at a Jan. 27 teleconference reporting results for the second quarter ended Dec. 31.
You may also be interested in...
PE Biosystems/Third Wave Technologies
Termination of a January acquisition pact under which PE Biosystems would have acquired the Madison, Wisconsin-based developer of nucleic acid technologies for stock valued in the $300 mil. range will not prevent the firms from continuing to pursue joint collaborations, including several active projects, PE says (1"The Gray Sheet" Jan. 31, p. 19). "Recent discussions...led both companies to conclude that their collective interests would be best served if the companies remain independent but continue to collaborate," PE says in a May 25 release
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.